<div id="readability-page-1"><p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report) shares gapped down prior to trading on Friday following insider selling activity. The stock had previously closed at $43.96, but opened at $42.91. Hims &amp; Hers Health shares last traded at $44.71, with a volume of 4,937,687 shares changing hands.</p><ul><li>Ozempic Boom: Hims &amp; Eli Lilly Lead Healthcare Bets</li></ul><p>Specifically,  CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $45.06, for a total value of $5,773,402.62. Following the completion of the sale, the chief executive officer directly owned 89,521 shares of the company's stock, valued at $4,033,816.26. The trade was a 58.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. </p><div><p><span></span><span>Get <strong>Hims &amp; Hers Health</strong> alerts:</span></p></div><h2>Analyst Upgrades and Downgrades</h2><p>HIMS has been the subject of a number of research reports. Zacks Research cut shares of Hims &amp; Hers Health from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday. Needham &amp; Company LLC  reaffirmed a &#34;hold&#34; rating on shares of Hims &amp; Hers Health in a report on Tuesday, August 5th. Deutsche Bank Aktiengesellschaft  reaffirmed a &#34;hold&#34; rating on shares of Hims &amp; Hers Health in a report on Wednesday, May 7th. Citigroup  reaffirmed a &#34;sell&#34; rating on shares of Hims &amp; Hers Health in a report on Monday, June 23rd. Finally, TD Cowen lowered shares of Hims &amp; Hers Health from a &#34;buy&#34; rating to a &#34;hold&#34; rating and dropped their price target for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Two equities research analysts have rated the stock with a Buy rating, eight have assigned  a Hold rating and three have issued  a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of &#34;Reduce&#34; and a consensus target price of $38.92.</p><ul><li>Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, &amp; Shift4</li></ul><p><b>Read Our Latest Analysis on HIMS</b></p><h2>Hims &amp; Hers Health Stock Up 1.2%</h2><p>The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The firm has a market capitalization of $10.05 billion, a price-to-earnings ratio of 55.57, a price-to-earnings-growth ratio of 2.93 and a beta of 2.08. The firm's 50-day moving average price is $51.92 and its 200 day moving average price is $45.76. </p><ul><li>MarketBeat Week in Review – 08/04 - 08/08</li></ul><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims &amp; Hers Health had a return on equity of 26.26% and a net margin of 9.63%.Hims &amp; Hers Health's revenue was up 72.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.06 EPS.  Hims &amp; Hers Health has set its Q3 2025 guidance at  EPS. FY 2025 guidance at  EPS. Sell-side analysts expect that  Hims &amp; Hers Health, Inc. will post 0.29 EPS for the current year. </p><h2>Institutional Trading of Hims &amp; Hers Health</h2><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Marex Group plc bought a new stake in shares of  Hims &amp; Hers Health during the 2nd quarter worth about $53,626,000.  Nomura Holdings Inc. grew its stake in shares of  Hims &amp; Hers Health by 151.4% in the 2nd quarter. Nomura Holdings Inc. now owns 161,052 shares of the company's stock worth $8,028,000 after purchasing an additional 96,997 shares during the last quarter.  Castleark Management LLC acquired a new position in shares of  Hims &amp; Hers Health in the 2nd quarter worth approximately $2,921,000.  Tower Research Capital LLC TRC grew its stake in shares of  Hims &amp; Hers Health by 54.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 38,285 shares of the company's stock worth $1,909,000 after purchasing an additional 13,473 shares during the last quarter.  Finally, SkyView Investment Advisors LLC acquired a new position in shares of  Hims &amp; Hers Health in the 2nd quarter worth approximately $226,000. 63.52% of the stock is currently owned by institutional investors. </p><h2>Hims &amp; Hers Health Company Profile</h2> (Get Free Report)<p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA. </p><h2>See Also</h2><ul><li>Five stocks we like better than Hims &amp; Hers Health</li><li>Why Are Stock Sectors Important to Successful Investing?</li><li>Small Cap, Big Potential: 3 Tech Disruptors You Should Know About</li><li>How to Use the MarketBeat Stock Screener </li><li>After Earnings Miss, Walmart Is Still a Top Consumer Staples Play</li><li>Top Biotech Stocks: Exploring Innovation Opportunities</li><li>How Cisco Is Building a New Growth Story for Investors</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p><p>While Hims &amp; Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HIMS

<p>Hims & Hers Health (NYSE:HIMS) shares gapped down to $42.91 following insider selling by CEO Andrew Dudum, who sold 128,127 shares at $45.06 each. The stock closed at $44.71 with a trading volume of nearly 5 million shares. Analysts have downgraded the stock, with Zacks changing its rating from "strong-buy" to "hold". The company reported Q2 earnings of $0.17 EPS, missing estimates, and revenue of $544.83 million, up 72.6% year-over-year. Institutional investors hold 63.52% of the stock.</p>

Hims & Hers Health (NYSE:HIMS) Shares Gap Down Following Insider Selling